Dataset Information


Effects of itaconate on gene expression in mouse CD8 T cells

ABSTRACT: The tumor microenvironment possesses multiple overlapping mechanisms that suppress anti-tumor immunity. Itaconate is a metabolite produced from the Krebs cycle intermediate cis-aconitate by the activity of immune-responsive gene 1 (IRG1). While it is known to be immune modulatory, the role of itaconate in anti-tumor immunity is unclear. Here, we demonstrate that myeloid-derived suppressor cells (MDSCs) secreted itaconate that can be taken up by CD8+ T cells and suppress their proliferation, cytokine production, and cytolytic activity. Metabolite profiling, stable-isotope tracing and metabolite supplementation studies indicated that itaconate suppressed biosynthesis of aspartate and serine/glycine in CD8+ T cells to attenuate their proliferation. Moreover, stromal deletion of IRG1 in mice bearing allografted tumors resulted in decreased tumor growth, inhibited the immune suppressive activities of MDSCs, reduced levels of itaconate in tumors, promoted anti-tumor immunity of CD8+ T cells, and enhanced the anti-tumor activity of anti-PD-1 antibody treatment. Importantly, we found a significant negative correlation between IRG1 expression and response to PD-1 immune checkpoint blockade in melanoma patients. Our findings not only reveal a previously unknown role of itaconate as an immune checkpoint metabolite secreted from MDSCs to suppress CD8+ T cells, but also establish IRG1 as a novel myeloid-selective target in immunometabolism to promote anti-tumor immunity and enhance the efficacy of immune checkpoint protein blockade.

ORGANISM(S): Mus musculus

PROVIDER: GSE190028 | GEO | 2022/11/15


Similar Datasets

2023-01-01 | GSE215195 | GEO
2024-07-08 | GSE230735 | GEO
2020-05-15 | GSE145950 | GEO
2024-02-14 | GSE235749 | GEO
2020-08-04 | GSE144787 | GEO
2023-01-15 | MTBLS5877 | MetaboLights
2024-03-19 | GSE253555 | GEO
2024-03-19 | GSE252242 | GEO
2024-03-19 | GSE252241 | GEO
2016-07-01 | E-GEOD-82043 | biostudies-arrayexpress